The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice

Journal of Neural Transmission

Volumn 114, Issue 2, 2007, Pages 205-209

  Youdim, M B H ^a   Grunblatt E ^a,b   Mandel, S ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Copper; D penicillamine; Iron; Metal chelator; MPTP; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLCYSTEINE; APOMORPHINE; CHELATING AGENT; COPPER; COPPER CHELATING AGENT; DOPAMINE; IRON CHELATING AGENT; PENICILLAMINE; SALICYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHELATION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; WILSON DISEASE;

ACETYLCYSTEINE; ANIMALS; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; IRON; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PENICILLAMINE; SALICYLIC ACID;

EID: 33846438299     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-006-0499-1     Document Type: Article

References (46)

1. D Acuna-Castrovie A Coto-Montes M Gaia Monti GG Ortiz RJ Reiter 1997 Melatonin is protective against MPTP-induced striatal and hippocampal lesions Life Sci 60 L23 L29
2. + neurotoxicity in mice Neurochem Res 26 59 64
3. G Battaglia CL Busceti L Cuomo FS Giorgi F Orzi A De Blasi F Nicoletti S Ruggieri F Fornai 2002 Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice Neuropharmacology 42 367 373
4. D Ben-Shachar G Eshel JP Finberg MB Youdim 1991 The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons J Neurochem 56 1441 1444
5. D Ben-Shachar N Kahana V Kampel A Warshawsky MB Youdim 2004 Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats Neuropharmacology 46 254 263
6. D Berg M Gerlach MB Youdim KL Double L Zecca P Riederer G Becker 2001 Brain iron pathways and their relevance to Parkinson's disease J Neurochem 79 225 236
7. S Bharath M Hsu D Kaur S Rajagopalan JK Andersen 2002 Glutathione, iron and Parkinson's disease Biochem Pharmacol 64 1037 1048
8. GJ Brewer 2005 Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment CNS Drugs 19 185 192
9. JL Cadet M Katz V Jackson-Lewis S Fahn 1989 Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats:behavioral and biochemical evidence Brain Res 476 10 15
10. G Cohen 2000 Oxidative stress, mitochondrial respiration, and Parkinson's disease Ann N Y Acad Sci 899 112 120
11. A Crowe EH Morgan 1996 The effects of iron loading and iron deficiency on the tissue uptake of 64Cu during development in the rat Biochim Biophys Acta 1291 53 59
12. DT Dexter FR Wells AJ Lees F Agid Y Agid P Jenner CD Marsden 1989a Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease J Neurochem 52 1830 1836
13. DT Dexter CJ Carter FR Wells F Javoy-Agid Y Agid A Lees P Jenner CD Marsden 1989b Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J Neurochem 52 381 389
14. D Di Monte MS Sandy MT Smith 1987 Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) Biochem Biophys Res Commun 148 153 160
15. TN Ferraro GT Golden M DeMattei TA Hare RG Fariello 1986 Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse Neuropharmacology 25 1071 1074
16. S Gal H Zheng M Fridkin MBH Youdim 2005 Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion J Neurochem 95 77 88
17. M Gassen A Gross MBH Youdim 1998 Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine Mov Disord 13 242 248
18. M Gassen Y Glinka B Pinchasi MBH Youdim 1996 Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction Eur J Pharmacol 308 219 225
19. M Gerlach D Ben-Shachar P Riederer MBH Youdim 1994 Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 79 793 807
20. E Grassmann M Kirchgessner JJ Kim 1983 Fe and Cu content in the liver, spleen, kidney and heart of growing rats with variable Fe and Cu supply Z Ernahrungswiss 22 124 137
21. E Grünblatt S Mandel T Berkuzki MBH Youdim 1999 Apomorphine protects against MPTP-induced neurotoxicity in mice Mov Disord 14 612 618
22. E Grünblatt S Mandel G Maor MBH Youdim 2001 Effects ofR-apomorphine and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss J Neurochem 77 146 156
23. S Hall JN Rutledge T Schallert 1992 MRI, brain iron and experimental Parkinson's disease J Neurol Sci 113 198 208
24. B Halliwell 2001 Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment Drugs Aging 18 685 716
25. K Jellinger W Paulus I Grundke-Iqbal P Riederer MBH Youdim 1990 Brain iron and ferritin in Parkinson's and Alzheimer's diseases J Neural Transm Park Dis Dement Sect 2 327 340
26. K Jellinger E Kienzel G Rumpelmair P Riederer H Stachelberger D Ben-Shachar MBH Youdim 1992 Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis J Neurochem 59 1168 1171
27. P Jenner CW Olanow 1996 Oxidative stress and the pathogenesis of Parkinson's disease Neurology 47 S161 S170
28. D Kaur F Yantiri S Rajagopalan J Kumar JQ Mo R Boonplueang V Viswanath R Jacobs L Yang MF Beal D DiMonte I Volitaskis L Ellerby RA Cherny AI Bush J Anderson 2003 Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease Neuron 37 899 909
29. DM Kaye S Gruskin AI Smith MD Esler 2000 Nitric oxide mediated modulation of norepinephrine transport: identification of a potential target for S-nitrosylation Br J Pharmacol 130 1060 1064
30. G Kunikowska P Jenner 2002 The distribution of copper, zinc- and manganese-superoxide dismutase, and glutathione peroxidase messenger ribonucleic acid in rat basal ganglia Biochem Pharmacol 63 1159 1164
31. J Lan DH Jiang 1997 Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice J Neural Transm 104 469 481
32. L Leggio G Addolorato L Abenavoli G Gasbarrini 2005 Wilson's disease: clinical, genetic and pharmacological findings Int J Immunopathol Pharmacol 18 7 14
33. H Mochizuki H Imai K Endo K Yokomizo Y Murata N Hattori Y Mizuno 1994 Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys Neurosci Lett 168 251 253
34. S Moussaoui MC Obinu N Daniel M Reibaud V Blanchard A Imperato 2000 The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease Exp Neurol 166 235 245
35. E Oestreicher GJ Sengstock P Riederer CW Olanow AJ Dunn GW Arendash 1994 Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study Brain Res 660 8 18
36. E Pileblad T Magnusson B Fornstedt 1989 Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum J Neurochem 52 978 980
37. P Riederer E Sofic WD Rausch B Schmidt GP Reynolds K Jellinger MBH Youdim 1989 Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains J Neurochem 52 515 520
38. C Rios R Alvarez-Vega P Rojas 1995 Depletion of copper and manganese in brain after MPTP treatment of mice Pharmacol Toxicol 76 348 352
39. TA Seaton P Jenner CD Marsden 1996 Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain J Neural Transm 103 315 329
40. J Sian DT Dexter AJ Lees S Daniel Y Agid F Javoy-Agid P Jenner CD Marsden 1994 lterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Ann Neurol 36 348 355
41. E Sofic P Riederer H Heinsen H Beckmann GP Reynolds G Hebenstreit MBH Youdim 1988 Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain J Neural Transm 74 199 205
42. JA Temlett JP Landsberg F Watt GW Grime 1994 Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis J Neurochem 62 134 146
43. MB Youdim D Ben-Shachar P Riederer 1993 The possible role of iron in the etiopathology of Parkinson's disease Mov Disord 8 1 12
44. MB Youdim G Stephenson D Ben Shachar 2004 Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28 Ann N Y Acad Sci 1012 306 325
45. L Zecca MB Youdim P Riederer JR Connor RR Crichton 2004 Iron, brain ageing and neurodegenerative disorders Nat Rev Neurosci 5 863 873
46. H Zheng LM Weiner O Bar-Am S Epsztejn ZI Cabantchik A Warshawsky MB Youdim M Fridkin 2005 Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases Bioorg Med Chem 13 773 778